The purpose of this study is to measure the effect of 30 mg RE104 on adjustment disorder symptoms (depressed mood or anxiety) compared to 1.5 mg RE104 in participants with cancer or other illnesses in order to decrease these symptoms.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Zev Nakamura
Psychiatry - General
Clinical or Medical
Interventional
Cancer (Bladder, Brain and Other Nervous System, Breast, Colorectal, Cervical, Head and Neck, Kidney, Liver, Lung, Melanoma, Pancreatic, Prostate, Sarcoma (bone and soft tissue), Stomach and Esophageal, Thyroid and Other Gland/Endocrine, Leukemia, Lymphoma, Multiple Myeloma, Uterine (endometrial), Ovarian)
Chronic Conditions
Mental and Emotional Health
25-2212
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
